Curis (CRIS) Set to Post Quarterly Earnings on Thursday

Curis (NASDAQ:CRIS) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Curis to post earnings of ($2.29) per share and revenue of $1.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Curis (NASDAQ:CRIS) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.95) by $2.93. On average, analysts expect Curis to post ($15.65) EPS for the current fiscal year and ($57.10) EPS for the next fiscal year.

Curis Stock Performance

Shares of NASDAQ CRIS opened at $0.66 on Tuesday. Curis has a 52-week low of $0.33 and a 52-week high of $31.80. The firm has a 50 day moving average price of $0.90 and a two-hundred day moving average price of $9.02. The stock has a market cap of $1.38 million, a P/E ratio of -0.05 and a beta of 3.11.

Analyst Upgrades and Downgrades

CRIS has been the topic of a number of recent research reports. Zacks Research upgraded shares of Curis from a “strong sell” rating to a “hold” rating in a report on Wednesday, September 9th. Wall Street Zen upgraded Curis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 22nd. HC Wainwright restated a “buy” rating on shares of Curis in a report on Monday, August 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $43.00.

About Curis

Curis, Inc is a clinical-stage biotechnology company focused on developing innovative therapeutics for the treatment of cancer. The company’s research and development activities center on targeted therapies designed to address biological pathways involved in tumor growth and immune regulation.

Curis’ lead investigational product is emavusertib, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The company has evaluated emavusertib in clinical studies for hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndromes and certain forms of non-Hodgkin lymphoma.